Search This Blog

Tuesday, November 12, 2019

ICU survivors commonly experience job loss after critical illness

In recent years, national attention has been drawn to the plight of patients who have experienced the unintended side effects of prolonged ICU care, such as memory loss, muscle weakness and depression. Now, in the largest review to date, a research team led by University of California San Diego School of Medicine have evaluated the short- and long-term employment impacts to ICU patients, with concerning findings.
Results of the study published in the November online edition of Thorax.
“We already know that more than 50 percent of patients surviving critical illness experience impairments in cognitive, physical, and/or mental health after ICU stays. We now can add delayed return-to-work and joblessness to the potential adverse outcomes,” said first author Biren Kamdar, MD, assistant professor of medicine, UC San Diego School of Medicine. “The good news is that awareness of these consequences is growing, with adoptable approaches to addressing them.”
Kamdar and a team of researchers from UCLA, UCSF, Johns Hopkins University, Intermountain Medical Center and Brigham Young University performed a systematic review and meta-analysis of more than 10,000 previously employed ICU patients to evaluate return-to-work following critical illness. Fifty-two studies were evaluated from sources including PubMed, Embase, PsycINFO, CINAHL, and Cochrane Library.
“We found that two-thirds, two-fifths, and one-third of previously employed ICU survivors are jobless 3, 12 and 60 months following hospital discharge,” said Kamdar. “Impacts ranged from unplanned job changes to complete job loss to early retirement. Survivors frequently required ongoing disability benefits with rates of 20 to 27 percent at one year, and 59 to 89 percent at 76 months.”
Jobless survivors were likely to transition from private to government-provided health care coverage. And, despite return to work, the majority of survivors incurred substantial lost earnings, totaling up to two-thirds of pre-ICU annual income.
Joblessness and delayed return to work, along with cognitive impairments and post-traumatic stress, are among the various problems making up “post intensive care syndrome” or PICS, a constellation of disabling and long-lasting impairments commonly affecting survivors of critical illness. Risk factors for PICS may include sepsis and respiratory failure, which are inherent to critical illness, and delirium and immobility, potentially modifiable conditions in the ICU.
“Survival is not enough. We are seeing that many patients get discharged from the ICU and then experience disabilities that significantly affect their quality of life,” said Kamdar. “We need to shift the paradigm of care in the ICU to include early and effective interventions aimed at helping patients get back to a normal life, including returning to work.”
The systematic review included studies involving outpatient ICU recovery programs aimed at helping patients understand and manage their impairments. Kamdar pointed out that clinical investigations are needed to design, evaluate and optimize vocational rehabilitation programs aimed at helping survivors return to work. A starting point could involve identifying patients’ occupation and anticipating possible post-ICU impairments that could impact their ability to return to work.
“Designing and evaluating novel ICU-based interventions is necessary to give patients a chance of having better long-term outcomes,” said Kamdar. “In coordination with employers, patients may be able to return to their chosen vocations.”
Kamdar noted that initiatives such as THRIVE, launched by the Society of Critical Care Medicine, may help ICU survivors and their families cope with PICS. Kamdar also highlighted the outpatient ICU recovery clinic at UC San Diego Health.
###
Co-authors of this paper include: Rajat Suri from UCLA; Mary Suchyta from Intermountain Healthcare; Kyle Digrande from UC San Diego; Kyla Sherwood from UCSF; Elizabeth Colantuoni, Victor Dinglas and Dale Needham from Johns Hopkins University; and Ramona Hopkins from Brigham Young University.

Anthrax may be the next tool in the fight against bladder cancer

Anthrax may soon help more people win the fight against bladder cancer, which the Centers for Disease Control and Prevention says strikes about 72,000 Americans each year and kills about 16,000, and is one of the most expensive cancers to treat.
The current treatments for bladder cancer are invasive for patients – who often must sit for hours at a time with a bladder full of an agent designed to kill cancer cells and tumors. Bladder cancer also is one of the most reoccurring for people diagnosed with the disease.
Now, researchers at Purdue University have come up with a way to combine the anthrax toxin with a growth factor to kill bladder cancer cells and tumors. The research is published in the Oct. 4 edition of the International Journal of Cancer.
“We have effectively come up with a promising method to kill the cancer cells without harming the normal cells in the bladder,” said R. Claudio Aguilar, an associate professor and the assistant head of biological sciences in Purdue’s College of Science. “It is basically like creating a special solution that targets cancer cells while leaving healthy cells alone.”
Aguilar said the bladder has its own protective layer, which saves the good cells from the anthrax mixture but offers no protection for the cancer cells and tumors. He said the Purdue system works within minutes – instead of the usual hours for bladder cancer treatment – to target the cancer cells in the bladder.
“We have seen outstanding results with our treatment,” said Aguilar, who works as part of a team focused on cell identity and signaling at the Purdue University Center for Cancer Research. “It is fast and effective, both of which are critical for people dealing with this devastating disease.”
Aguilar and his group worked with the Purdue teams led by Timothy Ratliff and Deborah Knapp to test their solution in dogs with bladder cancer who had run out of other treatment options. They found this new agent decreased the tumor size without causing any other side effects in the animals.
The Purdue team thinks a similar treatment may help people and animals with other cancers, including those affecting the lungs or skin.
###
The researchers also worked with partners in the Indiana University School of Medicine, the Massachusetts Institute of Technology and Harvard University.

Satsuma Pharmaceuticals EPS misses by $1.25

Satsuma Pharmaceuticals (NASDAQ:STSA): Q3 GAAP EPS of -$2.26 misses by $1.25.
Cash and equivalents of $118.9M.

Vaping Worse for Heart Than Cigarettes?

E-cigarette smokers were worse off than conventional cigarette smokers in terms of coronary microvascular vascular function, researchers found in a small study.
Physiologic changes between rest and a hand-grip exercise to simulate stress showed regular tobacco cigarette and e-cigarette users had fairly similar myocardial blood volume responses to stress right after a smoking session compared with non-smoking controls (-4.3% and -0.9% vs +2.7% from baseline).
However, the e-cigarette group did worse than the combustible cigarette group in change in myocardial blood velocity (-4.7% vs +34.7% for tobacco, P=0.005) and myocardial blood flow (-5.8% vs +30.5%, P=0.023).
And both groups were worse on those two measures than the controls (+66.8% and +72.1%, respectively), according to Florian Rader, MD, MSc, of the Smidt Heart Institute at Cedars-Sinai Medical Center, Los Angeles, and colleagues.
The study results were released ahead of presentation later this week as an oral abstract at the American Heart Association meeting in Philadelphia.
“The blunting of stress-induced increase of coronary blood flow associated with chronic e-cig use in humans is consistent with what is being seen in other vascular systems, in animals, and after acute use: endothelial dysfunction at the level of (or exceeding) that of combustible cigarette use,” commented Matthew Springer, PhD, of the University of California, San Francisco.
“We are seeing an emerging story that regardless of whether vaping involves less risk of cancer and less tar in the lungs than traditional smoking, the cardiovascular effects are substantial and indicate a level of cardiovascular risk that one really wants to avoid,” wrote Springer in an email to MedPage Today.
Vaping-related acute lung damage, dubbed “EVALI,” has already killed dozens, most of them young people under age 30. Recently, vitamin E acetate has been proposed as the common denominator among bronchoalveolar lavage samples of those who have fallen sick after e-cigarette or vape use.
Rader’s group noted that e-cigarettes and vaping devices rely on battery-powered aerosolization that delivers a mix of small molecules that can cross the alveolar-capillary barrier and enter into the circulation.
“What makes e-cigarettes so harmful to the heart and lungs is not just nicotine,” said Rader in a press release. “It’s the completely unknown bucket of manufactured products used to form vapors that is likely causing the most harm. This is what we believe is underlying the current public health problem.”
“It’s very clear that e-cigarettes have a detrimental effect on myocardial endothelial function, even a worse effect than classical cigarettes,” commented Daniel Duprez, MD, PhD, of the University of Minnesota, Minneapolis. And endothelial dysfunction, in turn, can lead to increased blood pressure and mark the beginning of atherosclerotic disease, he told MedPage Today.
“This is just adding to the evidence that in terms of heart disease, e-cigarettes are just as bad as cigarettes and might be even worse. That’s the picture emerging for lung disease, too,” said Stanton Glantz, PhD, also of the University of California, San Francisco, who was not involved in the study.
A total of 30 people participated in the present study, undergoing myocardial contrast echocardiography after overnight abstinence from smoking. Average age was 28 years, and this was a group of healthy adults who had normal tension and were not obese. There were only eight women in the study.
“However, the gender ratio in the vaping group was similar to that in the smoking group, so the observation that the vapers had essentially no myocardial flow response to stress, compared with a blunted but still present response in smokers, is especially strong and implies that switching from smoking to vaping may involve increased risks in some aspects of cardiovascular health,” Springer emphasized.
He pointed out that the authors didn’t report whether their non-cigarette-smoking participants were exposed frequently to secondhand smoke or are marijuana smokers.
Nevertheless, the public may have been getting the message that EVALI cases seem to mostly be associated with THC products and associated ingredients, potentially leading people who vape nicotine products to feel “immune” to all the risks of vaping — and that’s wrong, according to Springer.
There are other ways in which vaping nicotine e-cigarettes can lead to cardiovascular and pulmonary harm, he emphasized. “The public needs to hear about studies like this.”
The study was funded in part by the Tobacco Related Disease Research Program.
Springer, Glantz, and Duprez disclosed no relevant relationships with industry.

AbbVie’s Rinvoq shows positive action in ankylosing spondylitis study

A Phase 2/3 clinical trial, SELECT-AXIS 1, evaluating AbbVie’s (ABBV +3%) JAK inhibitor Rinvoq (upadacitinib) in adult patients with ankylosing spondylitis (AS) (a type of arthritis primarily affecting the spine) showed a treatment benefit. The results were presented at the American College of Rheumatology Annual Meeting in Atlanta.
The study met the primary endpoint of demonstrating a statistically significantly greater proportion of treated patients achieving ASAS40 (40% improvement in AS) at week 14 compared to placebo (52% vs. 26%; p<0.001).
Participants were naïve to biologic disease-modifying antirheumatic drugs and had failed to respond adequately to or were intolerant of nonsteroidal anti-inflammatory drugs (NSAIDs).
The FDA approved Rinvoq in August for rheumatoid arthritis. Late-stage studies in psoriatic arthritis, Crohn’s disease, atopic dermatitis, ulcerative colitis and giant cell arteritis are in process.

FibroGen adds to selloff, down 5% on bearish report

Embattled FibroGen (FGEN -4.5%) is down again today on a 4x surge in volume, adding to longs’ misery after yesterday’s 15% drop.
Muddy Waters Research added fuel to roxadustat safety profile-stoked worries with a short report published today on BuyersStrike that asserted the company under-reported deaths in a late-stage study.
Related ticker: AstraZeneca (AZN +0.6%)

Cardlytics EPS beats by $0.17, beats on revenue

Cardlytics (NASDAQ:CDLX): Q3 Non-GAAP EPS of $0.03 beats by $0.17; GAAP EPS of -$0.33 misses by $0.04.
Revenue of $56.42M (+63.2% Y/Y) beats by $6.4M.
Shares -0.6%.